Fundraising FoxSound Pharmaceuticals
Seattle, US · Delaware corporation
Find your way into Sound Pharmaceuticals
Sign up to see every warm intro you have to Sound Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sound Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Sound Pharmaceuticals (SPI) is a Seattle-based biotech developing drug therapeutics, including its lead candidate SPI-1005, to prevent and treat sensorineural hearing loss, tinnitus, and Meniere's disease. Its treatments target inner ear disorders for which there are currently no FDA-approved drugs.
Founders & leadership
Board
Reported raises · per SEC filings
Form D private placements$12.5M disclosed across 2 rounds · 2015–2018
▶$8.4MraisedJun 2018 · 5 investors · BiotechnologyRule 506(b)
- David GuyerDirector
- James C. TowneDirector
- Jonathan KilExecutive Officer, Director
- Joseph AshleyDirector
- John SullivanExecutive Officer
- Glenn KawasakiDirector
- Offering amount
- $10.4M
- Amount sold
- $8.4M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.1MraisedSep 2016 · 4 investors · BiotechnologyRule 506(b)
- Glenn KawasakiDirector
- James Paul RickeyExecutive Officer
- Jonathan KilExecutive Officer, Director
- Eric LynchExecutive Officer, Director
- Joseph AshleyDirector
- Offering amount
- $5M
- Amount sold
- $4.1M
- Minimum investment
- $300K
- First sale
- Aug 2015
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Sound Pharmaceuticals.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $160K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Sound Pharmaceuticals do?
- Sound Pharmaceuticals (SPI) is a Seattle-based biotech developing drug therapeutics, including its lead candidate SPI-1005, to prevent and treat sensorineural hearing loss, tinnitus, and Meniere's disease. Its treatments target inner ear disorders for which there are currently no FDA-approved drugs.
- Who founded Sound Pharmaceuticals?
- Sound Pharmaceuticals was founded by Jonathan Kil.
- How much funding has Sound Pharmaceuticals raised?
- Sound Pharmaceuticals has disclosed $12.5M raised across 2 rounds.
- Where is Sound Pharmaceuticals headquartered?
- Sound Pharmaceuticals is headquartered in Seattle, US.